Abstract
Selection of a feasible sequence and schedule of carboplatin in combination with topotecan for evaluation in advanced epithelial ovarian cancer (EOC). Women with stages III-IV EOC or primary peritoneal carcinoma without prior chemotherapy were assigned to consecutive cohorts evaluating a "forward" (carboplatin day 1, topotecan days 1-3), "reverse" (carboplatin day 3, topotecan days 1-3), or "extended reverse" sequence (carboplatin day 5, topotecan days 1-5). Patients received 4 cycles carboplatin-topotecan followed by 4 cycles carboplatin-paclitaxel. Feasibility was defined according to the cumulative proportion of patients with dose-limiting events (DLEs) during the first four cycles. Sixty-eight patients were enrolled across 5 cohorts. The forward sequence demonstrated unacceptable hematologic DLEs at the lowest topotecan dose (0.75 mg/m2/day x 3 days). The reverse sequence was feasible at 1.25 mg/m2/day x 3 days, with only 1/15 patients experiencing a DLE within 4 cycles, and 14/15 patients were able to receive 4 subsequent cycles of carboplatin-paclitaxel. The extended reverse sequence was associated with excessive DLEs at 1.00 mg/m2/day x 5 days. Prophylactic hematopoietic growth factors were not required. Higher doses of ...Continue Reading
References
Oct 19, 1994·Journal of the National Cancer Institute·T C ChouG J Bosl
Jun 19, 1996·Journal of the National Cancer Institute·S O'ReillyL B Grochow
Dec 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K SwenertonE Eisenhauer
Mar 6, 1998·Cancer Chemotherapy and Pharmacology·J MaJ H Schellens
Apr 2, 1998·Cancer Chemotherapy and Pharmacology·S RomanelliF Zunino
Mar 31, 2000·Gynecologic Oncology·M MarkmanK Hall
Jun 1, 2000·Gynecologic Oncology·M A BookmanW A Andersen
May 2, 2001·Gynecologic Oncology·G BolisF Parazzini
Mar 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Bois A duU Wagner
Apr 2, 2002·Gynecologic Oncology·Alan N GordonMichael Teneriello
Jul 12, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H GelderblomJ Verweij
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Sep 4, 2003·Journal of the National Cancer Institute·Andreas du BoisUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
Oct 10, 2003·Cancer·David Scott MillerD Scott McMeekin
Aug 7, 2004·Gynecologic Oncology·Alan N GordonJames A Young
Oct 29, 2005·Gynecologic Oncology·Howard S HochsterUNKNOWN New York Gynecologic Oncology Group (and phase II consortium) and the Eastern Cooperative Oncology
Citations
May 21, 2014·Journal of the National Cancer Institute·Michael A Bookman
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A BookmanLawrence M Roth
Dec 18, 2008·Future Oncology·Dirk O BauerschlagJakobus Pfisterer
Apr 11, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M A Bookman
Jan 15, 2008·Gynecologic Oncology·Howard HochsterFranco Muggia
Mar 21, 2007·Gynecologic Oncology·Deborah K ArmstrongUNKNOWN Gynecologic Oncology Group
Oct 9, 2007·Cancer Chemotherapy and Pharmacology·Dominique KoensgenUNKNOWN North-Eastern German Society of Gynecological Oncology Study Group-Ovarian Cancer